# ![@FractylHealth Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2766827876.png) @FractylHealth Fractyl Health

Fractyl Health posts on X about health, nasdaq, $guts, we are the most. They currently have [-----] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: undefined [#](/creator/twitter::2766827876/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2766827876/c:line/m:interactions.svg)

- [--] Week [---] -70%
- [--] Months [-----] +872%
- [--] Year [-----] -4.20%

### Mentions: undefined [#](/creator/twitter::2766827876/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2766827876/c:line/m:posts_active.svg)

- [--] Year [--] -75%

### Followers: [-----] [#](/creator/twitter::2766827876/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2766827876/c:line/m:followers.svg)

- [--] Week [-----] +0.27%
- [--] Months [-----] +24%
- [--] Year [-----] +25%

### CreatorRank: undefined [#](/creator/twitter::2766827876/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2766827876/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [exchanges](/list/exchanges)  [countries](/list/countries)  [finance](/list/finance) 

**Social topic influence**
[health](/topic/health), [nasdaq](/topic/nasdaq), [$guts](/topic/$guts) #6, [we are](/topic/we-are), [weight loss](/topic/weight-loss), [glp1](/topic/glp1), [germany](/topic/germany), [san antonio](/topic/san-antonio), [rates](/topic/rates), [the first](/topic/the-first)

**Top accounts mentioned or mentioned by**
[@obesityweek](/creator/undefined) [@wassimlaroussi3](/creator/undefined) [@stackdivs](/creator/undefined) [@wired](/creator/undefined) [@emilylmullin](/creator/undefined) [@washingtonpost](/creator/undefined) [@harithr](/creator/undefined) [@erictopol](/creator/undefined) [@inside_pm](/creator/undefined) [@danieljdrucker](/creator/undefined) [@agingroy](/creator/undefined) [@sofiasbio](/creator/undefined) [@prasanthab0112](/creator/undefined) [@rnaianalyst](/creator/undefined) [@manonthepen](/creator/undefined)

**Top assets mentioned**
[Fractyl Health, Inc. (GUTS)](/topic/$guts) [GLP1 (GLP1)](/topic/glp1)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Thank you @WIRED and @emilylmullin for today's coverage titled "A One-Time Shot for Type [--] Diabetes A Biotech Company Is On It." #genetherapy #type2diabetes #biotech #health"  
[X Link](https://x.com/anyuser/status/1678425264970186759)  2023-07-11T00:39Z [--] followers, [---] engagements


"Fractyl Health (Nasdaq: GUTS) announced the pricing of its initial public offering. https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-announces-pricing-initial-public-offering https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-announces-pricing-initial-public-offering"  
[X Link](https://x.com/FractylHealth/status/1753230075565056183)  2024-02-02T01:33Z [---] followers, [----] engagements


"Fractyl Health Inc. (Nasdaq: GUTS) is excited to share our findings at #DDW2024 Stop by booth #312 and dont miss Sundays plenary presentation titled poster presentation "Single-Dose GLP-1-Based Pancreatic Gene Therapy: Sustaining Weight Loss Post Semaglutide Discontinuation and Diminishing Hepatic Triglycerides in an Obesity Mouse Model." 103AB May [--] 4-5:30pm ET. #type2diabetes #health #obesity #genetherapy #biotech"  
[X Link](https://x.com/FractylHealth/status/1791919754438971550)  2024-05-18T19:52Z [---] followers, [---] engagements


"We were thrilled to share our latest research at @ObesityWeek and connect with brilliant minds dedicated to tackling #obesity and #T2D. Thank you to everyone who joined our presentations and engaged in insightful discussions Read more: #OW2024 https://bit.ly/3AkC1aa https://bit.ly/3AkC1aa"  
[X Link](https://x.com/FractylHealth/status/1854975739554075106)  2024-11-08T19:54Z [---] followers, [---] engagements


"BREAKING: We're excited to announce promising initial clinical results from the first patient in the REVEAL-1 open-labelcohort of our REMAIN-1 study. We're seeing positive results after one month of #GLP1 drug discontinuation alongside the Revita procedure in line with trends observed in prior Revita clinical studies. Additionally we're reporting significant progress in our REMAIN-1 pivotal study evaluating weight maintenance after GLP-1 discontinuation. With more than [---] patients enrolled across the first [--] clinical study sites in less than [--] months since first site activation this"  
[X Link](https://x.com/FractylHealth/status/1878802660960129077)  2025-01-13T13:53Z [---] followers, [----] engagements


"Exciting one-year follow-up data from #Germany shows positive results in lowering and maintaining both #WeightLoss and #BloodSugar. Learn more about the potential impact on people living with #obesity and #T2D: #FractylHealthNews https://bit.ly/3AfB1DT https://bit.ly/3AfB1DT"  
[X Link](https://x.com/FractylHealth/status/1821519515307458647)  2024-08-08T12:11Z [----] followers, [---] engagements


"Were continuing to take steps to make a meaningful difference for #patients. Read more about Fractyl Healths (#NASDAQ: $GUTS) Q2 financial results: #FractylHealthNews https://bit.ly/3YJupri https://bit.ly/3YJupri"  
[X Link](https://x.com/FractylHealth/status/1823814573444698444)  2024-08-14T20:10Z [----] followers, [---] engagements


"At Fractyl Health our mission is to innovate new solutions for people living with #obesity and #T2D. For Emily Sorrentine Associate Director Procedural Training Medical Affairs the people she works with each day are a testament to Fractyl Healths approach and values. #FractylForward https://twitter.com/i/web/status/1838602294327144902 https://twitter.com/i/web/status/1838602294327144902"  
[X Link](https://x.com/FractylHealth/status/1838602294327144902)  2024-09-24T15:32Z [----] followers, [---] engagements


"We've got some exciting news. we're rolling out a refreshed brand identity and website Our rebrand is a pivotal moment reflecting the transition of Fractyl Health: who we are where were headed & our commitment to our patients. See our new look at http://fractyl.com http://fractyl.com"  
[X Link](https://x.com/FractylHealth/status/1849860131275808878)  2024-10-25T17:06Z [----] followers, [---] engagements


"We are excited to announce that Fractyl Health will be presenting cutting-edge research at @ObesityWeek in San Antonio TX. Join us for our oral and poster presentations where we'll share the latest advancements in tackling the unmet need in obesity durable weight maintenance. Stay tuned for more updates #HealthcareInnovation #ObesityResearch #OW2024 #Fractyl https://twitter.com/i/web/status/1850949479832101135 https://twitter.com/i/web/status/1850949479832101135"  
[X Link](https://x.com/FractylHealth/status/1850949479832101135)  2024-10-28T17:15Z [----] followers, [---] engagements


"Were breaking the pattern of #obesity and #T2D. Read more about Fractyl Healths (#NASDAQ: $GUTS) Q3 financial results and our potentially novel approach to weight maintenance here: #FractylHealthNews https://bit.ly/4hMqGR2 https://bit.ly/4hMqGR2"  
[X Link](https://x.com/FractylHealth/status/1856445865591767273)  2024-11-12T21:16Z [----] followers, [----] engagements


"Weve had a banner year at Fractyl Health. From going public to presenting compelling data across the country to investors and scientists and receiving a Breakthrough Device designation from the FDA - we're celebrating our successes and looking #FractylForward to a big [----] full of critical catalysts. We're deeply appreciative of our employees our Board our investors our physician partners and most importantly our patients for propelling us forward each day and making significant strides in the fight against #obesity and #T2D. We look forward to continuing this momentum in 2025"  
[X Link](https://x.com/FractylHealth/status/1872704000740528305)  2024-12-27T18:00Z [----] followers, [---] engagements


"Were breaking the pattern of #obesity and #T2D. Read more about Fractyl Healths (#NASDAQ: $GUTS) Q4 and Full Year [----] financial results and our potentially novel approach to weight maintenance here: #FractylHealthNews #FractylForward https://bit.ly/3F4RQnl https://bit.ly/3F4RQnl"  
[X Link](https://x.com/FractylHealth/status/1896669208358105511)  2025-03-03T21:09Z [----] followers, [---] engagements


"We are pleased to share new 6-month open-label data from the REVEAL-1 Cohort marking another important milestone in our pursuit of innovative durable solutions for people living with #metabolicdisease. The findings reinforce an encouraging trend: Revita may help individuals maintain their weight after discontinuing GLP-1 drugs underscoring the potential for longer-lasting metabolic control in #obesity. Thank you to our participants investigators partners and the Fractyl team for advancing this important work. Read more about the data: *Revita is for Investigational Use Only in the U.S. under"  
[X Link](https://x.com/FractylHealth/status/1995883269619921260)  2025-12-02T15:50Z [----] followers, [---] engagements


"Fractyl Health (NASDAQ: $GUTS) today announced positive early data from the REVEAL-1 cohort of the ongoing REMAIN-1 pivotal study. Results show that the Revita procedure designed to address a root cause of obesity has the potential to prevent weight regain after GLP-1 drug discontinuation. With GLP-1 adoption surging and discontinuation rates rising these data point to a significant under-addressed commercial opportunity: providing a scalable non-pharmacologic solution to sustain weight loss without chronic drug use. Learn more: #FractylForward #Obesity #ClinicalTrial #DataAnnouncement"  
[X Link](https://x.com/FractylHealth/status/1907035647111573725)  2025-04-01T11:41Z [----] followers, [----] engagements


"#News for #Investors and #Media: At [--] months Revita patients lost an additional 2.5% of total body weight after stopping GLP-1 therapy while sham patients regained 10% (p=0.014). These randomized blinded data support the potential for Revita to be the first therapy for post-GLP-1 weight maintenance. Watch the results below and read the full press release: #ObesityCare #WeightLoss #GLP1 #Revita *Revita is for Investigational Use Only in the U.S. under Federal law* https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-announces-groundbreaking-data-remain-1-midpoint"  
[X Link](https://x.com/FractylHealth/status/1971586834183430510)  2025-09-26T14:45Z [----] followers, [----] engagements


"AtFractylHealth our team is driven by a shared mission: to transform care for people living with obesity and type [--] diabetes through durable impactful innovation. This monthwereproud tospotlight Lindsay Dee Legal Operations Manager & Senior Paralegal whose commitment to advancing meaningful change reflects the heart of our work. I hope people living with obesity can access treatments that really work; ones that go beyond managing symptoms to help them feel healthy and confident again.I believe in a future where obesity care supports lasting wellbeing even amid busy lives."  
[X Link](https://x.com/FractylHealth/status/2001365072497774748)  2025-12-17T18:53Z [----] followers, [----] engagements


"GLP-1s changed metabolic care but are not permanent solutions. A @WashingtonPost article featuring our CEO and co-founder @HarithR discusses how Fractyl Health is moving toward gene therapy for obesity and type [--] diabetes. Read more: https://www.washingtonpost.com/health/2026/01/24/fractyl-glp1-gene-therapy/ https://www.washingtonpost.com/health/2026/01/24/fractyl-glp1-gene-therapy/"  
[X Link](https://x.com/FractylHealth/status/2016149195435188554)  2026-01-27T14:00Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing